All News
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE:
⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS
Key message? Addt'l tx needed to avoid high GC doses
#ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
CV events in women w/ ARDs pregnancies:
-2.0% of 19,340 pregnant ARDs
Adjusted relative risk:
-4 fold in ARD
-15 fold in primary APS
-6 fold in SLE
-SLE + APS 18 fold
25-30% occur in early post partum!
Need for continued vigilance after delivery
@RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm ( View Tweet)
CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW
TheDaoIndex KDAO2011 ( View Tweet)
Always great to see UCSD represent at #ACR23!
Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events
30% of events occurred postpartum
@RheumNow Abs#0722 https://t.co/CqZedfOlBC
Robert B Chao, MD ( View Tweet)
#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc
Md Yuzaiful Md Yusof ( View Tweet)
Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects
Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi
@RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6
Robert B Chao, MD ( View Tweet)
#ACRBest @RheumNow https://t.co/u6DiQbebTF
Aurelie Najm ( View Tweet)
Plenary 1 #ACR23
CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko
Bella Mehta bella_mehta ( View Tweet)
Treatment intensification was associated with a higher ASDAS cut-off (2.7) value than the recommended one (≥2.1), the recommended cut-off could be too stringent or consider other factors than disease activity, Webers, El-Din Abst#0517 #ACR23 @RheumNow https://t.co/ZtBXhufxU1 https://t.co/MzvZQoFbvw
Dr. Antoni Chan ( View Tweet)
Should all of active moms with #SLE receive DVT prophylaxis post partum? High rates of VTE in #ARDs post partum #0722 #ACRbest #ACR23 @RheumNow @ACRheum Likely data driven by #SLE and maybe #RA and not all #autoimmune #rheumatic #disease. Large pop’n data from California https://t.co/sGJa5N6HUj
Janet Pope ( View Tweet)
Plenary talk by Dhital etc al, shows increased risk of acute CV events in pregnant rheumatic, SLE, APS pts, esp if nephritis or APL+. #ACR23 Abstract 0722 https://t.co/pG0PqzVtIU
Dr. John Cush RheumNow ( View Tweet)
Analysis from the DESIR cohort reveal that pregnancy does not aggravate imaging changes in axSpA.
Stat significant changes seen on Xray of LSIJ b4 & after delivery (p=0.037) but not worsening.
Do these findings also translate to⬇️pain/improved QOL?
#ACR23 ABST0513 @RheumNow https://t.co/s6xD2CaPwn
sheila ( View Tweet)
In a subgrp analysis of the SURPASS study by Dr @XBaraliakos et al, there was low spinal prog over 2 yrs in SEC & SDZ-ADL treated pts regardless of +/- Synd/⬆️CRP
Synd+ > CRP+ as predictor of radiog prog
Again, early dx = early tx
#ACR23 ABST0522 @RheumNow https://t.co/fGF4szPJbp
sheila ( View Tweet)
Higher disease activity and systemic inflammation at baseline associated with greater risk of MACE in bDMARD nonusers but not in users. bDMARD-specific benefits directly on MACE risk beyond reducing inflammation, Karpouzas et al Abst#0391 #ACR23 @RheumNow https://t.co/lfoccZffTW https://t.co/ASpKYQof1I
Dr. Antoni Chan ( View Tweet)
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels
Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc.
AE trended higher in normal CRP pts taking Tofa compared to placebo
@RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa
Robert B Chao, MD ( View Tweet)
Long term safety data for bimekizumab (IL17i) in Psa & axSpA
Overall as expected; increased infections (esp fungal/candida) & hepatic events
No new signals... uveitis flares is interesting
Need H2H of IL17's! IXE vs SEC vs BIM
@RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA
Mike Putman EBRheum ( View Tweet)
Are anti CCP3 the new anti CCP2 antibodies?
Not yet!
Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms
But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2
@RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw
Aurelie Najm ( View Tweet)
Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5
Dr. Antoni Chan ( View Tweet)